Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Safinamide (FCE-26743) 是一种可逆选择性单胺氧化酶 B (IC50 0.098μM)抑制剂,可减少多巴胺的降解,也是一种谷氨酸释放抑制剂(IC50 8μM)。它还能抑制多巴胺的再摄取。 Safinamide 还能阻断钠和钙通道。 Safinamide 的潜在的其他用途可能是帕金森病、不宁腿综合征和癫痫。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 279 | 现货 | ||
10 mg | ¥ 393 | 现货 | ||
25 mg | ¥ 659 | 现货 | ||
50 mg | ¥ 968 | 现货 | ||
100 mg | ¥ 1,430 | 现货 | ||
500 mg | ¥ 3,580 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 323 | 现货 |
产品描述 | Safinamide (FCE-26743) is a reversible and selective monoamine oxidase B (IC50 0.098μM) inhibitor, reducing the degradation of dopamine, and a glutamate release inhibitor (IC50 8μM). It also inhibits dopamine reuptake. Safinamide also blocks sodium and calcium channels. Potential additional uses of Safinamide might be Parkinson's disease, restless leg syndrome and epilepsy. |
靶点活性 | MAO-A:580 μM, MAO-B:98 nM |
体外活性 | Safinamide (1–300 µM) reduces the amplitude of the peak sodium currents in a concentration-dependent manner. When the holding potential is depolarized to -53 mV, the inhibitory effect of safinamide with a lower IC50 value (8 µM) in rat cortical neurons [1]. |
体内活性 | Daily intraperitoneal injections of Safinamide 1mg/kg were administered for 14 days and the treatment prior to MCAO significantly ameliorates MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impairs expression of tight junction protein occludin and ZO-1 in mice .Safinamide (intraperitoneal injection; 5 mg/kg, 15 mg/kg and 30 mg/kg) dose dependently inhibits the veratridine-induced GABA release and Glu release in vivo [2]. |
别名 | EMD1195686, FCE26743, FCE 26743, EMD-1195686, EMD 1195686, FCE-26743 |
分子量 | 302.34 |
分子式 | C17H19FN2O2 |
CAS No. | 133865-89-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (297.7 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.3075 mL | 16.5377 mL | 33.0753 mL | 82.6884 mL |
5 mM | 0.6615 mL | 3.3075 mL | 6.6151 mL | 16.5377 mL | |
10 mM | 0.3308 mL | 1.6538 mL | 3.3075 mL | 8.2688 mL | |
20 mM | 0.1654 mL | 0.8269 mL | 1.6538 mL | 4.1344 mL | |
50 mM | 0.0662 mL | 0.3308 mL | 0.6615 mL | 1.6538 mL | |
100 mM | 0.0331 mL | 0.1654 mL | 0.3308 mL | 0.8269 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Safinamide 133865-89-1 Metabolism Neuroscience MAO EMD1195686 FCE26743 FCE 26743 EMD-1195686 EMD 1195686 FCE-26743 Inhibitor inhibitor inhibit